Glycosylation patterns of kidney proteins differ in rat diabetic nephropathy

Kidney International

Volumn 87, Issue 5, 2015, Pages 963-974

  Ravidà, Alessandra ^a   Musante, Luca ^a   Kreivi, Marjut ^a   Miinalainen, Ilkka ^a   Byrne, Barry ^a   Saraswat, Mayank ^a   Henry, Michael ^b   Meleady, Paula ^b   Clynes, Martin ^b   Holthofer, Harry ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

chronic kidney disease; diabetes; proteomic analysis

Indexed keywords

AGGLUTININ; AGGLUTININ E; DIPEPTIDYL PEPTIDASE IV; GLYCOPROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PEANUT AGGLUTININ; PLANT LECTIN; RICINUS COMMUNIS AGGLUTININ I; STREPTOZOCIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; MASS SPECTROMETRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RAT; SALT TOLERANCE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; GLYCOSYLATION; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DISEASE PROGRESSION; GLYCOSYLATION; KIDNEY CORTEX; MALE; MASS SPECTROMETRY; PLANT LECTINS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84929132351     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.387     Document Type: Article

References (78)

1. World Health Organisation fact sheet N 312. August 2011.
2. Potenza MA, Nacci C, Gagliardi S et al. Cardiovascular complications in diabetes: lessons from animal models. Curr Med Chem 2011; 18: 1806-1819.
3. Bentata Y, Haddiya I, Latrech H et al. Progression of diabetic nephropathy, risk of end-stage renal disease and mortality in patients with type-1 diabetes. Saudi J Kidney Dis Transpl 2013; 24: 392-402.
4. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673-689.
5. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34: 973-995.
6. Bush M, Franke S, Rü ster C et al. Advanced glycation end-products and the kidney. Eur J Clin Inv 2010; 40: 742-755.
7. Hanover JA, Krause MW, Love DC. Bittersweet memories: linking etabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012; 13: 312-321.
8. Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J. Histochem. Cytochem 2012; 60: 976-986.
9. van den Born J, van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney int 1993; 43: 454-463.
10. Raats CJI, van den Born J, Berden JHM. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney int 2000; 57: 385-400.
11. Gil N, Goldberg R, Neuman T et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61: 208-216.
12. Vernier RL, Steffes MW, Sisson-Ross S et al. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 1992; 41: 1070-1080.
13. van den Born J, Pisa B, Bakker MAH et al. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem 2006; 281: 29606-29613.
14. Sharon N, Lis H. Lectins: cell-agglutinating and sugar-specific proteins. Science 1972; 177: 949-959.
15. Rü diger H, Gabius HJ. Plant lectins: occurrence, biochemistry, functions and applications. Glycoconj J 2001; 18: 589-613.
16. Rosenquist TH, Huff T. Lectin binding in the diabetic rat kidney. Histochem 1985; 83: 279-284.
17. Hawthorne GC, MacLellan JR, Mythen M et al. Studies on glomerular basement membrane in experimental diabetes using lectin Histochemistry in Winstar rats. Diabetologia 1986; 29: 495-499.
18. Holthofer H, Pettersson E, Tö rnroth T. Diabetes mellitus associated changes in glomerular compounds: a fluorescence microscopical study. Histochem J 1987; 19: 351-356.
19. Truong LD, Phung VT, Yoshikawa Y et al. Glycoconjugates in normal human kidney. A histochemical study using 13 biotinylated lectins. Histochemistry 1988; 90: 51-60.
20. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrol 2007; 12: 261-266.
21. Cho WC, Yip TT, Chung WS et al. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 2006; 99: 256-268.
22. Hye-Jin H, Baek YM, Kim SW et al. Differential expression of kidney proteins in streptozotocin-induced diabetic rats in response to hypoglycemic fungal polysaccharides. J Microbiol Biotechnol 2007; 17: 2005-2017.
23. Fugmann T, Borgia B, Révész C et al. Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Kidney Int 2011; 80: 272-281.
24. Smith DF, Song X, Cummings RD. Use of glycan microarrays to explore specificity of glycan-binding proteins. Methods Enzymol 2010; 480: 417-444.
25. Kirino Y, Sato Y, Kamimoto T et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200: 53-61.
26. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999; 1473: 4-8.
27. Tamura K, Manabe N, Uchio K et al. Characteristic changes in carbohydrate profile in the kidneys of hereditary nephrotic mice (ICGN Strain). J Vet Med Sci 2000; 62: 379-390.
28. Yan K, Khoshnoodi J, Ruotsalainen V et al. N-linked glycosylation is critical for the plasma membrane localization of nephrin. J Am Soc Nephrol 2002; 13: 1385-1389.
29. Vogtländer NP, Tamboer WP, Bakker MA et al. Reactive oxygen species deglycosilate glomerular alpha-dystroglycan. Kidney Int 2006; 69: 1526-1534.
30. Nicolaou N, Margadant C, Kevelarn SH et al. Gain of glycosylation in integrin a3 causes lung disease and nephrotic syndrome. J Clin Invest 2012; 122: 4375-4387.
31. Salmon AH, Ferguson JK, Burford JL et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012; 23: 1339-1350.
32. Weinhold B, Sellmeier M, Schaper W et al. Deficits in sialylation impair podocyte maturation. J Am Soc Nephrol 2012; 23: 1319-1328.
33. Kakani S, Yardeni T, Poling J et al. The Gne M712T mouse as a model for human glomerulopathy. Am J Pathol 2012; 180: 1431-1440.
34. Vogtländer NP, van der Vlag J, Bakker MA et al. Expression of sialidase and dystroglycan in human glomerular diseases. Nephrol Dial Transplant 2010; 25: 478-484.
35. Poland DC, Schalkwijk CG, Stehouwer CD et al. Increased alpha3-fucosylation of alpha1-acid glycoprotein in Type I diabetic patients is related to vascular function. Glycoconj J 2001; 8: 261-268.
36. Itoh N, Sakaue S, Nakagawa H et al. Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. Am J Physio Endocrinol Metab 2007; 293: E1069-E1077.
37. Sun AL, Deng JT, Guan GJ et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res 2012; 9: 301-308.
38. Alter ML, Ott IM, von Websky K et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119-130.
39. Durinx C, Lambeir A-M, Bosmans E et al. Molecular characterization of dipeptidyl peptidase activity in serum. Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000; 267: 5608-5613.
40. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
41. Khoshnoodi J, Hill S, Tryggvason K et al. Identification of N-linked glycosylation sites in human nephrin using mass spectrometry. J Mass Spectrom 2007; 42: 370-379.
42. Dietrich A, Mederos y Schnitzler M, Emmel J et al. N-linked protein glycosylation is a major determinant for basal TRPC3 and TRPC6 channel activity. J Biol Chem 2003; 278: 47842-47852.
43. Schlö ndorff J, del Camin D, Carrasquillo R et al. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J. Physiol 2009; 296: C558-C569.
44. Kerjaschki D, Sharkey J, Farquhar MG. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984; 98: 1591-1596.
45. Charest PM, Roth J. Localization of sialic acid in kidney glomeruli: regionalization in the podocyte plasma membrane and loss in experimental nephrosis. Proc Natl Acad Sci USA 1985; 82: 8508-8512.
46. Dekan G, Gabel C, Farquhar MG. Sulfate contributes to the negative charge of podocalyxin, the major sialoprotein in the glomerular filtration slits. Proc Natl Acad Sci USA 1991; 88: 5398-5402.
47. Gleberg H, Healy L, Whiteley H et al. In vivo enzymatic removal of a2-6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerur injury. Lab Invest 1996; 74: 907-920.
48. Kreisel W, Hildebrandt H, Mossner W et al. Oligosaccharide reprocessing and recycling of a cell surface glycoprotein in cultured rat hepatocytes. Biol Chem 1993; 374: 255-263.
49. Aït Slimane T, Lenoir C, Sapin C et al. Apical secretion and sialylation of soluble dipeptidyl peptidase IV are two related events. Exp Cell Res 2000; 258: 184-194.
50. Fan H, Meng W, Kilian C et al. Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. Eur J Biochem 1997; 246: 243-251.
51. Aertgeerts K, Ye S, Shi L et al. N-Linked glycosylation of dipeptidyl peptidase IV (Cd26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Prot Sci 2004; 13: 145-154.
52. Alfalah M, Jacob R, Naim HY. Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N-and O-glycans as well as association with lipid microdomains. J Biol Chem 2002; 277: 10683-10690.
53. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 2001; 23: 261-269.
54. Adama A, Leclair P, Montpas N, Abdull Koumbadinga G, Bachelard H, Marceau F. Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases. Neuropept 2010; 44: 69-75.
55. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: 91-98.
56. Candiano G, Bruschi M, Musante L et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004; 25: 1327-1333.
57. Shevchenko A, Tomas H, Havlis J et al. Ingel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006; 1: 2856-2860.
58. Sutton-Smith M, Dell A. Analysis of carbohydrates/glycoproteins by mass spectrometry. in: Cell Biology: A Laboratory Handbook (ed. Celis JE) (Elsevier Academic Press: San Diego, 2006 pp 415-425.
59. Varona A, Blanco L, Perez I et al. Expression and activity profiles of DPP IV/ CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 2010; 10: 193.
60. Florentin D, Sassi A, Roques BP. A highly sensitive fluorimetric assay for 'enkephalinase', a neutral metalloendopeptidase that releases Tyr-Gly-Gly from enkephalins. Anal Biochem 1984; 141: 62-69.
61. Tojo A, Onozato ML, Ha H et al. Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 2001; 116: 269-276.
62. Morelle W, Haslam SM, Ziak M et al. Characterization of the N-linked oligosaccharides of megalin (gp330) from rat kidney. Glycobiology 2000; 10: 295-304.
63. Mitic B, Lazarevic G, Vlahovic P et al. Diagnostic value of the aminopeptidase N, N-acetyl-b-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 2008; 30: 896-903.
64. Danielsen EM. Post-translational suppression of expression of intestinal brush border enzymes by fructose. J Biol Chem 1989; 264: 13726-13729.
65. Goldberg M, Peshkovsky C, Shifteh A et al. mu-Protocadherin, a novel developmentally regulated protocadherin with mucin-like domains. J Biol Chem 2000; 275: 24622-24629.
66. Chouinard RF, Meek RL, Cooney SK et al. Effects of amino acids and glucose on mesangial cell aminopeptidase a and angiotensin receptors. Kidney Int 2002; 61: S106-S109.
67. Herzig CM, Shoeppe W, Scherberich JE, Angiotensinase A. (Aminopeptidase A): properties of chromatography purified isoforms of human kidney. J Chromatogr 1992; 625: 73-82.
68. Koc B, Erten V, Yilmaz MI et al. The relationship between red blood cell Na/K-ATPase activities and diabetic complications in patients with type 2 diabetes mellitus. Endocrine 2003; 21: 273-278.
69. Zhang W, Murakawa Y, Wozniak KM et al. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006; 247: 217-223.
70. Barinka C, Šácha P, Sklenár Man P et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Prot Sci 2004; 13: 1627-1635.
71. Arbin V, Claperon N, Fournie-Zaluski M-C et al. Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats. Brit J Pharmacol 2000; 130: 1297-1304.
72. Lafrance M-H, Vezina C, Wang O et al. Role of glycosylation in transport and enzymic activity of neutral endopeptidase-24.11. Biochem J 1994; 302: 451-454.
73. Broccolini A, Gidaro T, Cristofaro De et al. Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle. J Neurochem 2008; 105: 971-981.
74. Stauber WT, Ong SH, Fritz VK et al. Protease inhibitor localization in control and streptozotocin-diabetic skeletal muscles. Histochem J 1983; 15: 1079-1086.
75. Geiger T, Lamri Y, Tran-Thi T-A et al. Biosynthesis and regulation of rat a1-inhibitor3, a negative acute-phase reactant of the macroglobulin family. Biochem J 1987; 245: 493-500.
76. Mathew R, Futterweit S, Valderrama E et al. Meprin-a in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Am J Physiol Renal Physiol 2005; 289: F911-F921.
77. Kadowaki T, Tsukuba T, Bertenshaw GP et al. N-Linked oligosaccharides on the meprin A metalloprotease are important for secretion and enzymatic activity, but not for apical targeting. J Biol Chem 2000; 275: 25577-25584.
78. Leuenberger B, Hahn D, Pischitzis A et al. Human meprinb: O-linked glycans in the intervening region of the type I membrane protein protect the C-terminal region from proteolytic cleavage and diminish its secretion. Biochem J 2003; 369: 659-665.